A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

BACKGROUND: Few prognostic models for overall survival (OS) are available for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with recently approved agents. We developed a prognostic index model using readily available clinical and laboratory factors from a phase III tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., Azad, A. A., Eigl, B. J., Heng, D. Y. C., Joshua, A. M., de Bono, J. S., Scher, H. I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769990/
https://www.ncbi.nlm.nih.gov/pubmed/26685010
http://dx.doi.org/10.1093/annonc/mdv594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769990/
https://www.ncbi.nlm.nih.gov/pubmed/26685010
http://dx.doi.org/10.1093/annonc/mdv594

Ejemplares similares